Cellular Events Involved in the Sensitization of Etoposide-resistant Cells by Inhibitors of Calcium-calmodulin-dependent Processes. Role for Effects on Apoptosis, DNA Cleavable Complex, and Phosphorylation
Overview
Pharmacology
Affiliations
Inhibitors of calcium-calmodulin-dependent processes, 1-[N,O-bis(1,5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-piperazine KN-62 and trifluoperazine (TFP), at non-cytotoxic concentrations (2 and 5 microM, respectively) enhanced etoposide (VP-16) cytotoxicity in Adriamycin-resistant (HL-60/ADR0.05) cells (3- to > 50-fold). In contrast to TFP, the inhibitor KN-62 was able to reverse resistance in HL-60/ADR0.05 cells at VP-16 concentrations that produced equivalent cytotoxicity in sensitive (HL-60/S) cells. Unlike TFP, the cellular accumulation of VP-16 in the presence of KN-62 was enhanced 1.5- to 2-fold in HL-60/S (MDR1 -ve) and HL-60/ADR0.05 (MDR1 +ve) cells. To achieve equivalent cytotoxicity, levels of VP-16 in the resistant cells were > 4-fold lower in the presence of KN-62 compared with treatment with VP-16 alone. The sensitizing effects of both KN-62 and TFP were due to enhancement (2- to 4-fold) of VP-16-induced topoisomerase II (TOPO II)-mediated DNA cleavable complex formation, and depletion of the 170 kDa (alpha) TOPO II isoform. The DNA damage induced by VP-16 in the presence of KN-62 or TFP resulted in the rapid induction of apoptosis and depletion of cells in "S" phase of the cell cycle. Both 5 microM TFP and 2 microM KN-62 enhanced the phosphorylation of 170 kDa TOPO II 1.6-fold and 1.5-fold, respectively. Results suggest that the inhibitory effect of KN-62 or TFP on calcium-calmodulin-dependent processes may be mechanistically involved in sensitizing resistant cells to VP-16 by enhancing TOPO II-mediated DNA damage.
Associations Between Polymorphism rs7214723 and the Prognosis of Patients With Lung Cancer.
Zhang H, Chen B, Zou Z, Feng J, Li Y, Wang Y Front Oncol. 2021; 11:757484.
PMID: 34868969 PMC: 8640188. DOI: 10.3389/fonc.2021.757484.
Mechanisms regulating resistance to inhibitors of topoisomerase II.
Ganapathi R, Ganapathi M Front Pharmacol. 2013; 4:89.
PMID: 23914174 PMC: 3729981. DOI: 10.3389/fphar.2013.00089.
Takai N, Ueda T, Kira N, Ishii T, Yoshida T, Koga S Tumour Biol. 2012; 33(4):1053-8.
PMID: 22290426 DOI: 10.1007/s13277-012-0339-x.
Fas expression prevents cholangiocarcinoma tumor growth.
Pickens A, Pan G, McDonald J, Vickers S J Gastrointest Surg. 1999; 3(4):374-81; discussion 382.
PMID: 10482689 DOI: 10.1016/s1091-255x(99)80053-5.
Pan G, Vickers S, Pickens A, Phillips J, Ying W, Thompson J Am J Pathol. 1999; 155(1):193-203.
PMID: 10393851 PMC: 1866679. DOI: 10.1016/S0002-9440(10)65113-9.